NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals Inc (NASDAQ:KALA) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.01. The company earned $1.45 million during the quarter, compared to analyst estimates of $3.56 million. View Kala Pharmaceuticals' Earnings History.

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Kala Pharmaceuticals.

5 brokers have issued 12-month price objectives for Kala Pharmaceuticals' shares. Their forecasts range from $6.00 to $51.00. On average, they expect Kala Pharmaceuticals' stock price to reach $18.20 in the next twelve months. This suggests a possible upside of 179.1% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

Media coverage about KALA stock has been trending somewhat negative on Sunday, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Kala Pharmaceuticals.

Kala Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 4,700,000 shares, an increase of 14.1% from the December 15th total of 4,120,000 shares. Based on an average daily volume of 451,100 shares, the short-interest ratio is currently 10.4 days. Approximately 17.6% of the company's shares are sold short. View Kala Pharmaceuticals' Current Options Chain.

Some companies that are related to Kala Pharmaceuticals include Homology Medicines (FIXX), Stoke Therapeutics (STOK), Frequency Therapeutics (FREQ), CannTrust (CNTTF), Provention Bio (PRVB), Cytokinetics (CYTK), ANI Pharmaceuticals (ANIP), Omeros (OMER), Urogen Pharma (URGN), ImmunoGen (IMGN), Retrophin (RTRX), Basilea Pharmaceutica (BPMUF), DiaMedica Therapeutics (DMCAF), Processa Pharmaceuticals (PCSA) and Flexion Therapeutics (FLXN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Exelixis (EXEL), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), REDHILL BIOPHAR/S (RDHL), TG Therapeutics (TGTX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX) and Iovance Biotherapeutics (IOVA).

(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.45%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

KALA stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $6.52.

Kala Pharmaceuticals has a market capitalization of $225.20 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]